{"id":2764,"date":"2017-08-12T11:12:57","date_gmt":"2017-08-12T11:12:57","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/2017\/08\/12\/kvaasi-teostatavusuuring-juhtumikontroll-mis-seostab-sugavat-lokaalset-hupertermilist-ravi-standardse-vahiravi-ja-kirjeldab-ravivastuse-mustreid-esho\/"},"modified":"2025-09-02T13:37:08","modified_gmt":"2025-09-02T13:37:08","slug":"kliiniline-uuring-hupertermia-2","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/et\/kliiniline-uuring-hupertermia-2\/","title":{"rendered":"Kvaasi teostatavusuuring, mis seostab s\u00fcgava lokaalse h\u00fcpertermia ravi standardsete v\u00e4hiravidega ja kirjeldab ravivastuse mustreid"},"content":{"rendered":"<h1 style=\"text-align: center;\"><a href=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/cartleESHOfinal.pdf\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvaasi teostatavusuuring, mis seostab s\u00fcgava lokaalse h\u00fcpertermia ravi standardsete v\u00e4hiravidega ja kirjeldab ravivastuse mustreid<\/span><\/span><\/a><\/h1>\n<h2 style=\"text-align: center;\"><a href=\"https:\/\/www.esho.info\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Andromedic h\u00fcpertermia kliiniline uuring &#8211; Euroopa H\u00fcpertermilise Onkoloogia Seltsi kongress 2014\u00a0<\/span><\/span><\/a><\/h2>\n<figure id=\"attachment_111\" aria-describedby=\"caption-attachment-111\" style=\"width: 568px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-111 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg\" alt=\"Kliiniline uuring h\u00fcpertermia kohta Andromedic: kvaasi teostatavusuuring (juhtum-kontroll), mis seob s\u00fcgava lokaalse h\u00fcpertermia HyDeep 600WM ravi standardsete v\u00e4hiravidega ja kirjeldab ravivastuse mustreid.\" width=\"568\" height=\"826\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response.jpg 568w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/02\/Quasi-feasibility-studycase-control-asscoaiting-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-206x300.jpg 206w\" sizes=\"auto, (max-width: 568px) 100vw, 568px\" \/><figcaption id=\"caption-attachment-111\" class=\"wp-caption-text\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kvaasi teostatavusuuring (juhtumikontroll), mis seob s\u00fcgava lokaalse h\u00fcpertermia HyDeep 600WM ravi standardsete v\u00e4hiravidega ja kirjeldab ravivastuse mustreid.<\/span><\/span><\/figcaption><\/figure>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sissejuhatus:<\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">See on esimene kliiniline uuring Hispaanias ja Andaluusias, mis \u00fchendab s\u00fcgava lokaalse h\u00fcpertermia standardsete v\u00e4hiravi meetoditega.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Materjalid ja meetodid:<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Eesm\u00e4rgid:<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Esiteks:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> anal\u00fc\u00fcsida h\u00fcpertermia kliinilist kasu, ravivastust, ravi teostatavust ja mugavust koos rahvatervise s\u00fcsteemi standardsete v\u00e4hiravidega. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Teiseks:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> anal\u00fc\u00fcsida elulemust, elukvaliteeti ja toksilisust (\u00fcldine ja spetsiifiline v\u00e4hi h\u00fcpertermia).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Uuringu \u00fclesehitus:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Prospektiivne, kvaasieksperimentaalne, juhtum-kontroll-uuring, milles h\u00fcpertermiaravi (6\u201310 seanssi sagedusega 2\u20133 n\u00e4dalas) manustati koos standardse kiiritusravi (RT), keemiaravi (KT) v\u00f5i m\u00f5lema kombinatsiooniga. Patsiente, kellel esinesid primaarsed kasvajad 9 asukohas v\u00f5i metastaatilised kasvajad ja keda raviti radikaalse v\u00f5i kombineeritud raviga, v\u00f5rreldi retrospektiivselt kahe kontrolljuhtumiga, keda raviti eelmisel aastal.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kaks faasi:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> esimene \u00f5ppefaas (20 patsienti). Teine aktiivse ravi faas, kus osales 97 patsienti, v\u00f5rreldes 196 kontrollgrupiga, keda raviti 2012. aastal m\u00f5lemas haiglas kiiritusravi v\u00f5i QT-intervalli raviga ilma h\u00fcpertermiata (kokku 293 patsienti).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00dcheksa kasvajakohta:<\/span><\/span><\/strong><\/p>\n<blockquote>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Emakakael, eesn\u00e4\u00e4re, p\u00f5is<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">K\u00f5hun\u00e4\u00e4re, opereerimatu pea ja kael<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ajukasvajad, preoperatiivne p\u00e4rasool<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Opereerimatu neoadjuvantravi kaugelearenenud rinnav\u00e4hi korral<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Mittev\u00e4ikerakuline kopsuv\u00e4hk (NSCLC)<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palliatiivne ravi erinevates kohtades<\/span><\/span><\/li>\n<\/ul>\n<\/blockquote>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tulemused:<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Esialgsed andmed nimekirjast:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 22 patsienti (9 Juan Roman Jimenezi haiglas ja 13 Carlos Haya haiglas).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sugu: 13 meest ja 9 naist.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Keskmine vanus: 55 aastat (34\u201376 aastat).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kasvaja asukoht: glioblastoom (2c), pea ja kael (7c), preoperatiivne p\u00e4rasool (3c), rind (3c1), kops (11c), eesn\u00e4\u00e4re (4c), emakakael (lc), sakroiliakaalse luu metastaas.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ravi:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> HyDeep 600WM h\u00fcpertermiaaparaat (Andromedic), mis teostab 10 seanssi 2\u20133 korda n\u00e4dalas, kestusega 1 tund, v\u00f5imsusega 150\u2013400 W, olenevalt standardse onkoloogilise ravi asukohast.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ravi katkestamise p\u00f5hjused:<\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Juan R Jim\u00e9nezi haigla Huelvas: 3 juhtu, infektsioon ravi asemel (tselluliit p\u00e4rasoolev\u00e4hi korral), emakaverejooks (emakakaelav\u00e4hk) ja vabatahtlik ravi katkestamine.<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Haya de Melaga haigla C: 2 patsienti, kellest \u00fcks kuuendal seansil talus ravi h\u00e4sti ja teine \u200b\u200bkuuendal seansil h\u00e4sti talutava edu t\u00f5ttu.<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Patsiendi tulemus:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 19 patsienti on elus ja ootavad ravivastuse hindamist ning 3 patsienti on surnud haiguse progresseerumise t\u00f5ttu (2 said ainult keemiaravi ja HT kasvaja retsidiivi t\u00f5ttu eelnevalt kiiritatud pea- ja kaelapiirkonnas ning \u00fcks patsient, kellel oli neelu kasvaja retsidiiv ja kes sai palliatiivset kiiritusravi ja HT).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tolerantsus: 81,2% patsientidest (18 p) m\u00e4rkis, et nad on rahul v\u00f5i v\u00e4ga rahul, ja 18,8% (4 p) m\u00e4rkis, et nad on vastuv\u00f5etavad.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Toksilisus: 1. astme p\u00f5letustunnet meenutavat toksilisust esines 8-l 22-st patsiendist (36,3%). Toksilisust ei esinenud 66,6% patsientidel. Valu\/eelsegu ravitavas piirkonnas, 1. aste (haavandilise rinna korral), \u00fchel patsiendil.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Meie esialgne kogemus n\u00e4itab ravi teostatavust riiklikus haiglas, rutiinse rutiinravi osana ilma erakordsete ressursside vajaduseta ja k\u00f5rge taluvusega.<\/span><\/span><\/strong><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">J\u00c4RELDUSED: Ravi on teostatav ja mugav 81,2%-l meie patsientidest riiklikus tervishoius\u00fcsteemis, kusjuures 33%-l on kerge toksilisus tingitud h\u00fcpertermia ravist. Patsientide sobiv valik on \u00fclioluline.<\/span><\/span><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kvaasi teostatavusuuring, mis seostab s\u00fcgava lokaalse h\u00fcpertermia ravi standardsete v\u00e4hiravidega ja kirjeldab ravivastuse mustreid Andromedic h\u00fcpertermia kliiniline uuring &#8211; Euroopa H\u00fcpertermilise Onkoloogia Seltsi kongress 2014\u00a0 Sissejuhatus: See on esimene kliiniline uuring Hispaanias ja Andaluusias, mis \u00fchendab s\u00fcgava lokaalse h\u00fcpertermia standardsete v\u00e4hiravi meetoditega. Materjalid ja meetodid: Eesm\u00e4rgid: Esiteks: anal\u00fc\u00fcsida h\u00fcpertermia kliinilist kasu, ravivastust, ravi teostatavust ja&hellip;<\/p>\n","protected":false},"author":1,"featured_media":1937,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[903,108],"tags":[],"class_list":["post-2764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-studii-clinice-et","category-uudised"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/2764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/comments?post=2764"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/posts\/2764\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media\/1937"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/media?parent=2764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/categories?post=2764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/et\/wp-json\/wp\/v2\/tags?post=2764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}